Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 49,384 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on July 10, 2006, and was notified to the Company on July 12, 2006.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees. No specific risks or contingencies are detailed in this text.
Investor Verification Points
- Verify the impact of the 49,384 share transfer on the total outstanding share count.
- Confirm the specific allocation of shares among participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full terms of the GSK Trust to understand the discretionary nature of the holdings.
- Check subsequent filings for any additional director transactions related to the GSK Trust.